Mitochondria & Light

Cellular energy is the new wellness frontier — and the claims have outrun the trials. This guide states plainly what the evidence supports about mitochondria, light, red-light devices, vitamin D, and peptides. It will disappoint anyone selling a protocol, which is rather the point.

Three claims that must never be blurred

Almost every mitochondrial pitch blurs three different statements. Kept separate, most of the confusion in this space disappears:

1. "This practice improves health, and mitochondria are plausibly involved." True for exercise, sleep, not smoking, and a decent diet. The health benefit is established — the mitochondrial share of the credit usually isn't.
2. "This practice measurably changes human mitochondria in a specific tissue." Exercise in skeletal muscle has substantial direct evidence — it is the best-established modifiable mitochondrial stimulus there is. Most other interventions have smaller or indirect datasets.
3. "This practice prevents disease because it improved mitochondria." The claim every ad implies, and the one that is almost never established.

Light and mitochondria: four things, not one

"Light" is not a single intervention, and treating it as one is the signature error of this category. Four separate domains, four separate evidence bases:

• Daylight at the eyes — the principal environmental signal for circadian timing. High-certainty, and the core of what OPSIN plans daily. (Our Light & Sleep guide covers this pathway.)
• Solar UV on skin — makes vitamin D, and is a proven human carcinogen. Both facts, held together, are why OPSIN bounds every sun recommendation with a burn-safe window.
• Vitamin D status — essential for bone and mineral physiology; correcting real deficiency matters. But the 2024 Endocrine Society guideline recommends against routine testing and above-RDA dosing in most healthy adults, and in the VITAL trial (25,871 adults, 2,000 IU/day), supplementation did not significantly reduce invasive cancer incidence. Raising vitamin D above adequacy has not been shown to "optimize" mitochondria.
• Red / near-infrared devices (photobiomodulation) — a real research field with condition-specific clinical uses, and the most oversold corner of the space. A 2025 umbrella review of 15 meta-analyses spanning 200+ randomized trials found no high-certainty outcome across the indications assessed, and the proposed cytochrome-c-oxidase mechanism remains debated. A panel study at one wavelength and dose does not validate the panel being sold to you at another.

The peptide corner: research, not retail

Mitochondrial medicine is producing real tools — in September 2025 the FDA granted accelerated approval to elamipretide for Barth syndrome, an ultra-rare genetic disease. That is a milestone for a 12-patient pivotal trial in a specific disease — not an approval for aging, fatigue, or recovery. Meanwhile MOTS-c and the peptides sold by wellness clinics sit on the FDA's list of compounding substances with significant safety risks — unestablished identity, purity, dose, and long-term safety. OPSIN does not recommend or sell peptides, and treats "mitochondrial peptide" marketing as the clearest available test of whether a source is honest.

What actually has the evidence

The strongest mitochondrial "protocol" is anticlimactic: regular aerobic and resistance exercise (the one intervention with substantial direct human tissue evidence), adequate sleep, daytime outdoor light with UV-Index-appropriate protection, not smoking, a nutrient-adequate diet, and treating real deficiencies and real diseases. No single consumer test measures "mitochondrial health," and no lamp, fast, or supplement substitutes for the list above.

Educational content, not medical advice — and deliberately not a "mitochondrial protocol." Fatigue with red flags belongs with a clinician. Claims here are drawn from our full mitochondria evidence review (107 sources; publication in preparation) and are cited inline to primary sources and agencies. See our Medical Disclaimer.